6-months Outcome of the Effects of Sacubitril/Valsartan Combination in the Treatment of Chronic Heart Failure

Description

The study included 64 patients over the age of 38 who were treated at the Eurasia Hospital with a diagnosis of CHF. The diagnosis of CHF was confirmed on the basis of anamnesis, objective and instrumental examination methods. Eligibility criteria: history of chronic heart failure; circulatory failure (functional class II-IV, NHYA); left ventricular ejection fraction <40%. Exclusion criteria: acute myocardial infarction; hypertrophic cardiomyopathy; congenital heart defects; patients under 25 years of age; heart failure in oncology patients. In order to clarify the diagnosis and monitor the dynamics of the disease, a detailed anamnesis was collected in each patient, 2-dimensional echocardiography and Doppler echocardiography, 6-minute walking test examinations were used to measure the saturation of oxygen in the blood with a pulse oximeter, standard ECG examination, to assess the structural-geometric and functional parameters of the left ventricle of patients and the methods for determining the level of sodium B peptide in the blood were used. ECG, BNP determination, EcoGq, and 6-minute walking test were used to differentiate patients selected for the study based on anamnestic data and clinical signs. In conclusion, we have concluded that the addition of sacubitril / valsartan complex to the treatment of CHF patients is of great important.